Viridian Therapeutics IncDE
For the period ended Dec 31, 2023. Filed Feb 27, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 27, 2024
VRDN$30.19+6.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(in thousands, except share and per share data)
| December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $102,827 | $155,579 |
| Short-term investments | 374,543 | 268,971 |
| Prepaid expenses and other current assets | 9,006 | 6,521 |
| Unbilled revenue - related party | 102 | 102 |
| Total current assets | 486,478 | 431,173 |
| Property and equipment, net | 1,672 | 1,326 |
| Operating lease right-of-use asset | 1,670 | 1,610 |
| Other assets | 604 | 982 |
| Total assets | $490,424 | $435,091 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $2,239 | $14,234 |
| Accrued liabilities and other (including related party of $374 and $1,146 as of December 31, 2023 and 2022, respectively) | 24,108 | 18,827 |
| Current portion of deferred revenue - related party | 288 | 288 |
| Total current liabilities | 26,635 | 33,349 |
| Long-term debt, net | 20,205 | 4,645 |
| Deferred revenue - related party | 573 | 861 |
| Other liabilities | 989 | 1,172 |
| Total liabilities | 48,402 | 40,027 |
| Commitments and contingencies | ||
| Stockholders’ equity: | ||
| Preferred stock, series A non-voting convertible preferred stock, $0.01 par value; 435,000 shares authorized; 172,435 and 188,381 shares issued and outstanding as of December 31, 2023 and 2022, respectively | 78,235 | 85,470 |
| Preferred stock, series B non-voting convertible preferred stock, $0.01 par value; 500,000 shares authorized; 143,522 and 51,210 shares issued and outstanding as of December 31, 2023 and 2022, respectively | 128,281 | 56,677 |
| Common stock, $0.01 par value; 200,000,000 shares authorized; 53,986,112 and 41,305,947 shares issued and outstanding as of December 31, 2023 and 2022, respectively | 540 | 414 |
| Additional paid-in capital | 960,536 | 741,067 |
| Accumulated other comprehensive gain (loss) | 338 | (390) |
| Accumulated deficit | (725,908) | (488,174) |
| Total stockholders’ equity | 442,022 | 395,064 |
| Total liabilities and stockholders’ equity | $490,424 | $435,091 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.